Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | F2 | P00734 | 3/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tosifen SCHEMBL29387539 | 1.00 | GAA (1.00) | GAANPC1RAB9ALMNAF2 | |
| SCHEMBL11755955 | 0.86 | GAA (0.76) | GAANPC1RAB9ALMNAALDH1A1 | |
| SCHEMBL20335034 | 0.86 | GAA (0.75) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL20335036 | 0.86 | GAA (0.75) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL20335042 | 0.84 | GAA (0.72) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL20335002 | 0.83 | GAA (0.70) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL20335001 | 0.83 | GAA (0.70) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL23467914 | 0.82 | GAA (0.69) | GAALMNAALDH1A1CA2CA7 | |
| SCHEMBL20335121 | 0.82 | GAA (0.69) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL20335120 | 0.82 | GAA (0.69) | GAALMNAF2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4016291-A | CARDIAC DISORDERS INCLUDING ARRHYTHMIA | SCHERING CORPORATION (US) | 1977-04-05 | — | — | US | claimed |
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | disclosed |
| US-9089522-B2 | Method of reducing total cholesterol level by administering matrilin-2 polypeptide | MERCK SHARP & DOHME CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8598320-B2 | Anti-PCSK9 and methods for treating lipid and cholesterol disorders | MERCK SHARP & DOHME CORP. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8257921-B1 | NRIP1 regulation of apolipoprotein A1 | SCHERING CORPORATION (US) | 2012-09-04 | — | — | US | disclosed |
| WO-2012054438-A1 | ANTI-PCSK9 | SCHERING CORPORATION (US) | 2012-04-26 | — | — | WO | disclosed |
| CN-102232088-A | Anti-PCSK9 and methods for treating lipid and cholesterol disorders | SCHERING CORP | 2011-11-02 | — | — | CN | disclosed |
| US-20110150875-A1 | EGF-A DOMAIN-MEDIATED MODULATION OF PCKS9 FOR TREATING LIPID DISORDERS | MERCK SHARP & DOHME CORP. | 2011-06-23 | — | — | US | disclosed |
| EP-2285399-A2 | EGF-A DOMAIN-MEDIATED MODULATION OF PCSK9 FOR TREATING LIPID DISORDERS | Schering Corporation (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20110033465-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2205639-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009143367-A2 | EGF-A DOMAIN-MEDIATED MODULATION OF PCSK9 | SCHERING CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009055783-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-1385548-B1 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1541175-A2 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | Schering Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| CN-1582168-A | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORP (US) | 2005-02-16 | — | — | CN | disclosed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| US-4016291-A | CARDIAC DISORDERS INCLUDING ARRHYTHMIA | SCHERING CORPORATION (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033465-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | GAA 196/4885NPC1 16/4885RAB9A 1958/4885 |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | GAA 196/4885NPC1 16/4885RAB9A 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.